TRVI
Trevi Therapeutics Inc

1,806
Mkt Cap
$1.53B
Volume
926,084.00
52W High
$14.39
52W Low
$4.22
PE Ratio
-32.10
TRVI Fundamentals
Price
$12.50
Prev Close
$11.92
Open
$11.84
50D MA
$11.34
Beta
0.66
Avg. Volume
1.52M
EPS (Annual)
-$0.4698
P/B
8.05
Rev/Employee
$0.00
$313.53
Loading...
Loading...
News
all
press releases
MAI Capital Management Cuts Stock Holdings in Trevi Therapeutics, Inc. $TRVI
MAI Capital Management lowered its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 88.4% in the 3rd quarter, according to its most recent Form 13F filing with the...
MarketBeat·10h ago
News Placeholder
More News
News Placeholder
Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect?
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 102.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·7d ago
News Placeholder
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Brokerages
Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been assigned a consensus rating of "Buy" from the eleven analysts that are presently covering the stock, MarketBeat.com...
MarketBeat·24d ago
News Placeholder
Tejara Capital Ltd Trims Stock Position in Trevi Therapeutics, Inc. $TRVI
Tejara Capital Ltd cut its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 88.6% in the third quarter, according to its most recent disclosure with the Securities and...
MarketBeat·29d ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 6.5% - Here's Why
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 6.5% - Time to Sell...
MarketBeat·1mo ago
News Placeholder
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) Trevi Therapeutics Announces...
PR Newswire·1mo ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 6.3% - Here's Why
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 6.3% - Here's Why...
MarketBeat·2mo ago
News Placeholder
Flputnam Investment Management Co. Raises Stock Holdings in Trevi Therapeutics, Inc. $TRVI
Flputnam Investment Management Co. grew its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 1,105.4% during the third quarter, according to the company in its most recent...
MarketBeat·2mo ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Trading 5.7% Higher - Time to Buy?
Trevi Therapeutics (NASDAQ:TRVI) Stock Price Up 5.7% - Should You Buy...
MarketBeat·3mo ago
News Placeholder
Trevi Therapeutics, Inc. $TRVI Shares Acquired by Vivo Capital LLC
Vivo Capital LLC grew its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 28.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·3mo ago
<
1
2
...
>

Latest TRVI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.